ACEi to ARNi: "The Switch" An Evidence Based Review
<p>Heart failure affects approximately 6.5 million adults in the United States, and the cost to healthcare system is tremendous [1]. Effective treatment for this very important disease is constantly evolving. The most significant change in the recent past has been the development of ARNI (Sacu...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2020-10-30.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | <p>Heart failure affects approximately 6.5 million adults in the United States, and the cost to healthcare system is tremendous [1]. Effective treatment for this very important disease is constantly evolving. The most significant change in the recent past has been the development of ARNI (Sacubitril/ Valsartan) for treatment of heart failure [2].</p><p><br></p> |
---|---|
DOI: | 10.17352/2455-2976.000154 |